MIAMI--(BUSINESS WIRE)--Nov. 1, 2005--DOR BioPharma, Inc. (AMEX: DOR) (“DOR” or the “Company”), announced today that it has received notice from the American Stock Exchange (the “AMEX”) indicating that it no longer complies with the AMEX’s continued listing standards and that it intends to proceed with removal of the Company’s common stock from listing and registration on the AMEX. The AMEX has permitted the Company’s common stock to be listed pursuant to a plan period, which expired on October 15, 2005. AMEX determined that the Company was not in compliance with the requirement that it maintain more than $6 million of stockholders’ equity as it has sustained losses from continuing operations and/or net losses in three of its four most recent fiscal years.
